Purpose: To evaluate sociodemographic and clinical factors with postoperative complications after cataract surgery at academic medical centers in the United States. Setting: 16 U.S. academic medical centers contributing to the Sight Outcomes Research Collaborative (SOURCE) big data repository. Design: Retrospective, multicenter cohort study. Methods: Adults undergoing cataract surgery between 2010 and 2023 were identified from the SOURCE database. Sociodemographic and clinical predictors including race, ethnicity, primary language, and prior intraocular surgery were assessed. Postoperative complications within 6 months were identified using Current Procedural Terminology/International Classification of Diseases codes. Multivariate cox regression estimated hazard ratios with 95% confidence intervals. Results: 78 565 eyes were analyzed (mean age 70.8 ± 8.9 years, 59% female, 12.6% Black). At 6 months, 1.49% of eyes developed a complication and 0.10 developed a severe adverse complication. Independent predictors of any complication included male sex (hazard ratio [HR] 1.14; P < .01), Black race (HR 1.66; P < .01), complex surgery (HR 1.23; P < .01), combined intraocular procedures (HR 1.33; P < .01), prior intraocular surgery (HR 1.18; P < .01), and poorer preoperative vision (HR 1.10; P < .01). Severe adverse complications were more likely among men (HR 1.54; P = .02) and those with poorer vision (HR 1.62; P < .01), but less likely with increasing age (HR 0.95; P < .01), urban residence (HR 0.33; P < .01), and having 1 or more children in the household (HR 0.32; P = .03). Conclusions: Sociodemographic and clinical factors that increased risk of postoperative outcomes after cataract surgery included Black race, male sex, and poor preoperative vision. Older age, urban residence, and children in the household were protective. Incorporating social determinants of health into perioperative risk stratification may improve surgical equity and outcomes.

Mitochondrial dysfunction and oxidative stress have been suggested as potential contributors to the initiation and progression of primary open-angle glaucoma (POAG). Nicotinamide and pyruvate are important in the human body for maintaining metabolic function and preserving cytoskeletal structures. Both substances show an age-dependent decline in humans which may contribute to metabolic dysfunction and POAG vulnerability. Pilot works suggest their consumption may help prevent retinal ganglion cell deterioration under elevated intraocular pressure (IOP) and oxidative stress. Currently, there are no approved POAG treatments to mitigate risks from non-IOP drivers of disease, including oxidative stress. The purpose of this review is to summarize and critically evaluate interventional studies that have investigated nicotinamide and pyruvate supplementation in attempts to treat metabolic dysfunction in POAG patients. A review of the relevant literature from October 1979 to November 2025 was performed using related search terminologies through PubMed, ClinicalTrials.gov, and Google Scholar, and by reference cross-matching of all related articles. Current pilot data suggests that supplementation with nicotinamide and pyruvate demonstrates certain aspects of retinal neuroprotection and produces short-term improvements in visual function. However, much of the existing work has been conducted in animal models, and human study data are severely limited in scope and duration. Several clinical trials are registered as being in progress that aim to determine the chronic effects of nicotinamide and pyruvate in humans. Long-term longitudinal investigations with significantly larger and diverse sample sizes tied to functional and structural outcomes are needed for the safety and potential clinical utility of nicotinamide and pyruvate for POAG.

Introduction: Suicide is a growing public health issue in the United States. Healthcare visits in the year prior to suicide death, including those to emergency departments (ED) and inpatient settings, may be missed opportunities for risk-screening and intervention delivery. Our objective in this study was to evaluate the distribution of hospital visits of suicide decedents in the year prior to death by setting (ED and inpatient), last visit proximity to death, and presence of suicide risk factors, and to consider each setting’s potential for reaching those at risk of suicide. Methods: Using linked data from the Illinois Hospital Discharge Data Set and the Illinois Violent Death Reporting System, we examined suicide decedent hospital visits 365 days prior to suicide death. We described the distribution of visits by setting (ED vs inpatient), timing of the last visit prior to death, and groupings of visit primary diagnosis codes, as per the International Classification of Diseases, 10th Revision, reflecting suicide risk (deliberate self-harm, suicidal ideation, mental health disorders, and substance use disorder). The study was conducted between 2022–2025. Results: Of the 2,562 suicide decedents, 960 (37.4%) had a visit in the year preceding their death. The 960 decedents had a total of 3,131 visits, an average of 3.3. per person. Of those visits, 2,002 (63.9%) were to the ED. However, there was a greater proportion of last visits to an inpatient unit (687, 60.9%) that occurred under 180 days of death compared to last ED visits (1,060, 52.1%), P < .05). Inpatient visits also had higher percentages of visits for each of the suicide risk-diagnosis code groups compared to ED visits; deliberate self-harm, 22.2% (n = 251) vs 6.8% (n = 136); suicidal ideation 29% (n = 327) vs 8.6% (n = 173); mental health disorders, 5.7% (n = 64) vs 3.1% (n = 62); and substance use disorder, 75.1% (n = 848) vs 35.3% (n = 706), P < .05. Among both inpatient and ED visits, substance use was the most prevalent of the primary diagnosis suicide risk-factor groups endorsed, although inpatient visits had a statistically significant higher proportion of primary diagnosis codes for substance use than ED visits, 75.1% (n = 848) and 35.3% (n = 706), respectively, all P < .05. Conclusion: We found the proportion of suicide decedents with a hospital visit in the year prior to death was lower than other studies found for primary care settings. However, this does not mean that broad-based suicide screening and interventions would not be of value in hospital settings.7,14 Inpatient visits were fewer in number but a greater proportion of visits in closer proximity to suicide death and with suicide risk factors. This suggests that EDs may be better suited to broad-based screening and inpatient settings to targeted intervention efforts. Inpatient visits involving primary diagnosis suicide-risk factors may offer more easily identifiable opportunities for suicide prevention compared to those in ED settings, based on prevalence and temporal and logistical factors. Future interventions could consider how to systemically integrate risk screenings in both settings, particularly for patients with a diagnosis of substance use disorder.